摘要
通过临床药师参与心内科1例限制性心肌病的药物治疗:针对重度水肿合并低钠、低钾、低蛋白,选用利尿剂托伐普坦。针对患者白蛋白低,改用白蛋白结合率低的普伐他汀替代阿托伐他汀(蛋白结合率>98%),降低药物的肝肾毒性。
Clinical pharmacists implementing pharmaceutical care in drug treatment of a patient with restrictive cardiomyopathy combined right heart failure,severe edema,hyponatremia,hypokalemia,hypoproteinemia is reviewed in this article.Instead of furosemide,tolvaptan was recommended for its little effect on serum potassium and better security role on serum sodium.Potassium-sparing drugs should not be reused.Besides,atorvastatin was replaced with pravastatin which has lower albumin binding rate to reduce the toxicity of liver and kidney.
出处
《药学与临床研究》
2014年第2期177-179,共3页
Pharmaceutical and Clinical Research
关键词
临床药师
限制性心肌病
利尿剂
阿托伐他汀
Clinical pharmacist
Restrictive cardiomyopathy
Diuretics
Atorvastatin
Analysis and intervention
